On June 6, 2024, Pluristem Therapeutics held its annual shareholder meeting, at which all proposals were passed, including the adoption of audited comprehensive financial statements and board of directors' reports through December 31, 2023, as well as the re-election of Dr. Jin-Song Wang and Dr. Yiping Rong as executive directors, and Dr. Albert R. Collinson as an independent non-executive director. In addition, the board of directors was authorized to determine director remuneration, Ernst & Young was reappointed as auditor, and the board of directors was authorized to issue and repurchase shares. All resolutions were passed with over 99% of the vote in favor, except for the seventh and ninth resolutions, which received 85.82% and 99.50% of the vote in favor, respectively. The meeting was chaired by Dr. Jin-Song Wang, and all directors attended in person or electronically.

On June 6, 2024, Pluristem Therapeutics held its annual shareholder meeting, at which all proposals were passed, including the adoption of audited comprehensive financial statements and board of directors' reports through December 31, 2023, as well as the re-election of Dr. Jin-Song Wang and Dr. Yiping Rong as executive directors, and Dr. Albert R. Collinson as an independent non-executive director. In addition, the board of directors was authorized to determine director remuneration, Ernst & Young was reappointed as auditor, and the board of directors was authorized to issue and repurchase shares. All resolutions were passed with over 99% of the vote in favor, except for the seventh and ninth resolutions, which received 85.82% and 99.50% of the vote in favor, respectively. The meeting was chaired by Dr. Jin-Song Wang, and all directors attended in person or electronically.